Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
187actual
Sites
58
Countries
China, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-09 | actual | When the study began enrolling |
| Primary completion | 2025-03-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive-stage Small-cell Lung Cancer
Intervention
- Drug: Ifinatamab Deruxtecan (I-DXd) — also filed as DS-7300a
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC
measured Up to approximately 36 months
Publications
- PMID 41086386 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed